Online Resources

For easy access to a wealth of information on migraine and migraine treatment, below is a list of Web sites you may find helpful. Many will help you connect with information from your peers and other medical resources, others are Web sites you can refer your patients to for answers about migraine.

American Academy of Neurology
Valuable resources for medical specialists worldwide who are committed to improving the care of patients with neurological diseases.
http://www.aan.com/professionals/index.cfm?a=0&fc=1

American Council for Headache Education
A nonprofit patient/health professional partnership dedicated to advancing the treatment and management of headache.
http://www.achenet.org

American Headache Society
Brings together physicians and other health providers from various fields and specialties to share concepts and developments about headache and related conditions.
http://www.ahsnet.org

Mind Over Migraine
Tools and tips that can help your patients better manage their migraines and gain more control. The site includes podcasts and a migraine simulator.
http://www.mindovermigraine.com

National Headache Foundation
Everything from the latest in diagnosis and treatment to tips for helping your patients live happier, healthier lives while coping with headaches.
http://www.headaches.org

Ortho-McNeil Migraine Solutions
Patient-friendly site for information on migraine condition, symptoms, triggers, diagnosis, and treatment solutions.
http://www.migrainesolutions.com

Ortho-McNeil Neurologics
A website focused exclusively on solutions that improve neurological health.
http://www.ortho-mcneilneurologics.com

Back to the Top

Indication
AXERT tablets are indicated for the acute treatment of migraine with or without aura in adults.
AXERT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of AXERT have not been established for cluster headache, which is present in an older, predominantly male population.

IMPORTANT SAFETY INFORMATION
AXERT tablets should be used only when a clear diagnosis of migraine has been established. AXERT, like other triptans, has been associated with coronary vasospasm and therefore should not be given to patients with ischemic heart disease or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm (including Prinzmetal's variant angina), or other significant underlying cardiovascular disease. AXERT, like other triptans in this class, should not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by risk factors (family history, high cholesterol, high blood pressure, diabetes, or obesity). Because AXERT may increase blood pressure, it should not be given to patients with uncontrolled hypertension.

The development of a potentially life-threatening serotonin syndrome may occur with triptans, including AXERT treatment, particularly when combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If combined treatment with AXERT and an antidepressant is clinically warranted, patients should be closely observed for signs and symptoms of the serotonin syndrome such as mental status changes, hyperthermia, diaphoresis, labile blood pressure, tachycardia, hyperreflexia, incoordination and/or gastrointestinal symptoms, especially during treatment initiation and dosage escalation. Patients with the serotonin syndrome require immediate medical attention.

The most common side effects are nausea, sleepiness, paresthesia, headache and dry mouth.

Ask your healthcare professional about the side effects and other important considerations before taking AXERT.

For more detailed information, please see full Prescribing Information.

Celexa and Lexapro are registered trademarks of Forest Laboratories.
Paxil is a registered trademark of Glaxo Smith Kline.
Symbyax, Prozac/Sarafem and Cymbalta are registered trademarks of Eli Lilly.
Zoloft is a registered trademark of Pfizer.
Luvox is a registered trademark of Solvay.
Effexor is a registered trademark of Wyeth.

©Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2003-2008. All rights reserved. Licensed from Almirall Prodesfarma. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy.

Ortho-McNeil Neurologics, division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. publishes this site and is solely responsible for its contents. The TOPAMAX360.com, RAZADYNEER360.com, TOPAMAXEPILEPSY360.com, and AXERT360.com sites are directly affiliated with OMN360.com and the same terms of use apply across all sites.

Capitalized product names are trademarks of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

This information is intended for use by our customers, patients, and healthcare professionals in the United States only. Ortho-McNeil-Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States.